Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Caribou Biosciences (CRBU) EBIT (2020 - 2025)

Caribou Biosciences (CRBU) has disclosed EBIT for 6 consecutive years, with -$29.4 million as the latest value for Q3 2025.

  • On a quarterly basis, EBIT rose 23.11% to -$29.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$154.1 million, a 6.71% increase, with the full-year FY2025 number at -$148.3 million, up 10.97% from a year prior.
  • EBIT was -$29.4 million for Q3 2025 at Caribou Biosciences, up from -$47.6 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of -$13.2 million in Q1 2021 to a low of -$47.6 million in Q2 2025.
  • A 5-year average of -$29.7 million and a median of -$30.0 million in 2022 define the central range for EBIT.
  • Peak YoY movement for EBIT: plummeted 607.94% in 2021, then surged 44.86% in 2023.
  • Caribou Biosciences' EBIT stood at -$20.4 million in 2021, then crashed by 49.86% to -$30.6 million in 2022, then dropped by 22.45% to -$37.4 million in 2023, then decreased by 3.83% to -$38.9 million in 2024, then grew by 24.37% to -$29.4 million in 2025.
  • Per Business Quant, the three most recent readings for CRBU's EBIT are -$29.4 million (Q3 2025), -$47.6 million (Q2 2025), and -$38.9 million (Q4 2024).